← Oncology Approval Tracker

FDA DECISION ·

Sarclisa + carfilzomib + dexamethasone

isatuximab-irfc with carfilzomib and dexamethasone · Sanofi

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after one to three prior lines of therapy.

LAMPGEN ANALYSIS

Why it matters

This adds an anti-CD38 antibody to a carfilzomib and dexamethasone backbone in relapsed myeloma.

What research teams should watch

Reconcile earlier regimens and synchronize antibody infusion with the carfilzomib schedule.

PRIMARY RECORDS

Sources